title: [A patient with recurrent gastric cancer who developed TS-1 induced hand-foot syndrome].
abstract: Hand-foot syndrome (HFS) is a rare adverse reaction to oral fluoropyrimidine TS-1, which contains the dihydropyrimidine dehydrogenase (DPD) inhibitor. We treated a recurrent gastric cancer patient with chronic renal failure who developed grade 2 HFS, grade 2 conjunctivitis and grade 3 stomatitis soon after TS-1 administration. Those symptoms improved with the administration of vitamin B6, topical emollient therapy, and so on. We thought that the continuous elevation of serum 5-FU concentration, due to the accumulation of DPD inhibitor from the renal dysfunction, led to the development of HFS, although the participation of 5-FU metabolites such as F-beta-alanine cannot be ruled out.
authors.affiliation: Dept. of Surgery, Tokyo Metropolitan Komagome Hospital.
authors.forename: Kuniyoshi
authors.initials: K
authors.lastname: Arai
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Iwasaki
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kimura
authors.forename: Keiichi
authors.initials: K
authors.lastname: Takahashi
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Yamaguchi
authors.forename: Shigenori
authors.initials: S
authors.lastname: Honma
authors.forename: Toshio
authors.initials: T
authors.lastname: Takahashi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D003231:Conjunctivitis / Q000139:chemically induced; D004338:Drug Combinations; D005533:Foot Dermatoses / Q000139:chemically induced*; D006229:Hand Dermatoses / Q000139:chemically induced*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D010094:Oxonic Acid / Q000009:adverse effects*; D011355:Prodrugs / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D013274:Stomach Neoplasms / Q000188:drug therapy*; D013280:Stomatitis / Q000139:chemically induced; D013577:Syndrome; D005641:Tegafur / Q000009:adverse effects*; D025101:Vitamin B 6 / Q000627:therapeutic use
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011355:Prodrugs; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D025101:Vitamin B 6